Logo image of EQ

EQUILLIUM INC (EQ) Stock Fundamental Analysis

NASDAQ:EQ - Nasdaq - US29446K1060 - Common Stock - Currency: USD

0.4456  +0.04 (+10.65%)

Premarket: 0.44 -0.01 (-1.26%)

Fundamental Rating

2

Overall EQ gets a fundamental rating of 2 out of 10. We evaluated EQ against 553 industry peers in the Biotechnology industry. While EQ seems to be doing ok healthwise, there are quite some concerns on its profitability. EQ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EQ had negative earnings in the past year.
EQ had a negative operating cash flow in the past year.
In the past 5 years EQ always reported negative net income.
In the past 5 years EQ always reported negative operating cash flow.
EQ Yearly Net Income VS EBIT VS OCF VS FCFEQ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of EQ (-83.61%) is worse than 71.43% of its industry peers.
EQ has a Return On Equity of -132.23%. This is comparable to the rest of the industry: EQ outperforms 40.51% of its industry peers.
Industry RankSector Rank
ROA -83.61%
ROE -132.23%
ROIC N/A
ROA(3y)-45.84%
ROA(5y)-43.62%
ROE(3y)-98.95%
ROE(5y)-79.65%
ROIC(3y)N/A
ROIC(5y)N/A
EQ Yearly ROA, ROE, ROICEQ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100 -150

1.3 Margins

EQ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EQ Yearly Profit, Operating, Gross MarginsEQ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

EQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
EQ has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EQ has more shares outstanding
EQ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EQ Yearly Shares OutstandingEQ Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EQ Yearly Total Debt VS Total AssetsEQ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

EQ has an Altman-Z score of -15.67. This is a bad value and indicates that EQ is not financially healthy and even has some risk of bankruptcy.
EQ has a Altman-Z score of -15.67. This is amonst the worse of the industry: EQ underperforms 81.01% of its industry peers.
EQ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.67
ROIC/WACCN/A
WACC9.82%
EQ Yearly LT Debt VS Equity VS FCFEQ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.70 indicates that EQ has no problem at all paying its short term obligations.
EQ has a worse Current ratio (2.70) than 67.81% of its industry peers.
EQ has a Quick Ratio of 2.70. This indicates that EQ is financially healthy and has no problem in meeting its short term obligations.
EQ's Quick ratio of 2.70 is on the low side compared to the rest of the industry. EQ is outperformed by 66.18% of its industry peers.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 2.7
EQ Yearly Current Assets VS Current LiabilitesEQ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

2

3. Growth

3.1 Past

EQ shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.33%.
EQ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.75%.
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-19.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, EQ will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.60% on average per year.
Based on estimates for the next years, EQ will show a quite strong growth in Revenue. The Revenue will grow by 19.44% on average per year.
EPS Next Y-280.65%
EPS Next 2Y-120.94%
EPS Next 3Y-51.08%
EPS Next 5Y11.6%
Revenue Next Year-100%
Revenue Next 2Y-52.55%
Revenue Next 3Y12.09%
Revenue Next 5Y19.44%

3.3 Evolution

EQ Yearly Revenue VS EstimatesEQ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
EQ Yearly EPS VS EstimatesEQ Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EQ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EQ Price Earnings VS Forward Price EarningsEQ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EQ Per share dataEQ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A cheap valuation may be justified as EQ's earnings are expected to decrease with -51.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-120.94%
EPS Next 3Y-51.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EQ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EQUILLIUM INC

NASDAQ:EQ (7/28/2025, 8:25:04 PM)

Premarket: 0.44 -0.01 (-1.26%)

0.4456

+0.04 (+10.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-06 2025-08-06
Inst Owners19.59%
Inst Owner Change0.43%
Ins Owners24.24%
Ins Owner Change0%
Market Cap15.92M
Analysts42
Price Target1.02 (128.9%)
Short Float %4.01%
Short Ratio0.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.17%
Min EPS beat(2)30.44%
Max EPS beat(2)49.89%
EPS beat(4)4
Avg EPS beat(4)71.7%
Min EPS beat(4)30.44%
Max EPS beat(4)106.47%
EPS beat(8)8
Avg EPS beat(8)59.13%
EPS beat(12)11
Avg EPS beat(12)77.81%
EPS beat(16)12
Avg EPS beat(16)57.23%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-32.14%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.52
P/FCF N/A
P/OCF N/A
P/B 1.5
P/tB 1.5
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.85
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -83.61%
ROE -132.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.84%
ROA(5y)-43.62%
ROE(3y)-98.95%
ROE(5y)-79.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.82
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.72%
Cap/Sales 0.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.7
Quick Ratio 2.7
Altman-Z -15.67
F-Score3
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)111.69%
Cap/Depr(5y)164.16%
Cap/Sales(3y)0.71%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y-280.65%
EPS Next 2Y-120.94%
EPS Next 3Y-51.08%
EPS Next 5Y11.6%
Revenue 1Y (TTM)-19.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-52.55%
Revenue Next 3Y12.09%
Revenue Next 5Y19.44%
EBIT growth 1Y-8.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-296.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-299.89%
OCF growth 3YN/A
OCF growth 5YN/A